Valuation DaShenLin Pharmaceutical Group Co., Ltd.

Stocks

End-of-day quote Shanghai S.E. 2026-10-16			5-day change	1st Jan Change
18.61 ^CNY	-0.69%		-0.80%	+5.62%

10-14	Dashenlin Pharmaceutical to Redeem Dashen Convertible Bonds	MT
10-12	DaShenLin Pharmaceutical to Pay H1 Dividend on Oct. 19	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	33,307	37,585	28,359	17,151	20,066	21,194	-	-
Change	-	12.85%	-24.55%	-39.52%	17%	5.62%	-	-
Enterprise Value (EV) ¹	32,838	36,233	27,369	15,778	16,831	17,854	17,434	17,139
Change	-	10.34%	-24.46%	-42.35%	6.67%	6.08%	-2.35%	-1.69%
P/E	42.1x	36.3x	24.2x	18.6x	16.3x	14.3x	12.4x	10.9x
PBR	6.3x	6.24x	4.16x	2.49x	2.72x	2.7x	2.48x	2.31x
PEG	-	1.2x	1.8x	-0.9x	0.5x	0.7x	0.8x	0.8x
Capitalization / Revenue	1.99x	1.77x	1.16x	0.65x	0.73x	0.72x	0.65x	0.59x
EV / Revenue	1.96x	1.71x	1.12x	0.6x	0.61x	0.6x	0.54x	0.48x
EV / EBITDA	13.6x	19.2x	12.9x	4.65x	4.39x	4.66x	4.15x	3.68x
EV / EBIT	31.6x	25.5x	16.8x	10.5x	8.26x	7.68x	6.6x	5.72x
EV / FCF	117x	13.1x	19.7x	9.51x	3.44x	10.4x	6.24x	5.27x
FCF Yield	0.86%	7.61%	5.09%	10.5%	29.1%	9.66%	16%	19%
Dividend per Share ²	0.3472	0.5	0.31	0.31	0.49	0.9418	1.043	1.222
Rate of return	1.19%	1.52%	1.24%	2.06%	2.78%	5.06%	5.6%	6.57%
EPS ²	0.6944	0.9083	1.03	0.81	1.08	1.304	1.5	1.701
Distribution rate	50%	55%	30.1%	38.3%	45.4%	72.2%	69.5%	71.8%
Net sales ¹	16,759	21,248	24,531	26,497	27,502	29,540	32,521	35,823
EBITDA ¹	2,408	1,883	2,119	3,395	3,833	3,828	4,204	4,651
EBIT ¹	1,041	1,421	1,632	1,501	2,038	2,324	2,643	2,997
Net income ¹	791.2	1,036	1,166	914.8	1,235	1,486	1,711	1,937
Net Debt ¹	-469.2	-1,352	-989.8	-1,373	-3,236	-3,340	-3,760	-4,056
Reference price ²	29.24	33.00	24.90	15.06	17.62	18.61	18.61	18.61
Nbr of stocks (in thousands)	1,138,968	1,138,947	1,138,902	1,138,848	1,138,848	1,138,855	-	-
Announcement Date	4/27/22	4/27/23	4/28/24	4/25/25	4/23/26	-	-	-